These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 14510013)

  • 1. Bortezomib in multiple myeloma.
    Meisler AI
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib for myeloma -- much ado about something.
    Dispenzieri A
    N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib: the subtle line between drug-induced peripheral neuropathy and post-herpetic neuralgia.
    Focosi D
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):E16-7. PubMed ID: 19717373
    [No Abstract]   [Full Text] [Related]  

  • 5. Images in clinical Medicine. Bortezomib-induced skin lesions.
    Agterof MJ; Biesma DH
    N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
    Velasco R; Petit J; Clapés V; Verdú E; Navarro X; Bruna J
    J Peripher Nerv Syst; 2010 Mar; 15(1):17-25. PubMed ID: 20433602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide for bortezomib-resistant multiple myeloma.
    Briani C; Berno T; Campagnolo M; Zambello R
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906
    [No Abstract]   [Full Text] [Related]  

  • 9. Bortezomib.
    Paramore A; Frantz S
    Nat Rev Drug Discov; 2003 Aug; 2(8):611-2. PubMed ID: 12908468
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
    Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
    El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
    Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib in multiple myeloma.
    Faix JD
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14507954
    [No Abstract]   [Full Text] [Related]  

  • 13. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
    Colvin LA; Johnson PR; Mitchell R; Fleetwood-Walker SM; Fallon M
    J Clin Oncol; 2008 Sep; 26(27):4519-20. PubMed ID: 18802169
    [No Abstract]   [Full Text] [Related]  

  • 14. Perspective on the current use of bortezomib in multiple myeloma.
    San-Miguel J; Bladé J
    Haematologica; 2006 Jul; 91(7):871-2. PubMed ID: 16818272
    [No Abstract]   [Full Text] [Related]  

  • 15. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
    Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer research. Taking garbage in, tossing cancer out?
    Garber K
    Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
    Kenealy MK; Prince HM; Hönemann D
    Pharmacotherapy; 2006 Aug; 26(8):1205-6; discussion 1206. PubMed ID: 16863501
    [No Abstract]   [Full Text] [Related]  

  • 18. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
    Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
    J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma.
    Kyle RA; Rajkumar SV
    N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
    [No Abstract]   [Full Text] [Related]  

  • 20. [Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology].
    Gotoh A; Ohyashiki K; Oshimi K; Usui N; Hotta T; Dan K; Ikeda Y; ;
    Rinsho Ketsueki; 2006 Dec; 47(12):1521-7. PubMed ID: 17233470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.